The Hebrew University of Jerusalem’s Yissum Research Development Company has introduced a novel method for detecting retinal micro-aneurysms that pose a high risk of leakage, a primary cause of diabetic blindness.
The novel method, patented by Yissum, will provide early diagnosis and treatment of the condition by minimising damage and saving vision.
Go deeper with GlobalData
A team of scientists, including Dr Yaakov Nahmias from the Center for Bioengineering at the Hebrew University of Jerusalem, developed a computational method to identify microvascular regions with a high risk of leakage based on fluid dynamics, which will help ophthalmologists to identify micro-aneurysms with high risk of leakage using adaptive optics.
The team also found that high risk is correlated with increased level of a protein called Von Willebrand factor (vWF), which is linked with early development of diabetic blindness.
Retinal microaneurysms reduce vision as they lead to fluid leakage from blood vessels and retinal edema.
However, localised leakage can be detected and treated using laser ablation in order to slow the progression of diabetic blindness.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataYissum CEO Yaacov Michlin said; “The novel method developed by Nahmias will allow experts to rapidly identify and treat those microaneurysms that pose a high-risk of leakage, minimising edema and saving vision.
“Moreover, the scientists open the route for targeted therapy or clinical detection using vWF, which they show serves as a protein marker for risky regions in the retina.
“By enabling early detection of high-risk areas, treatment of diabetic retinopathy can shift from a reactive treatment to a preventive one, not only preventing blindness but also saving millions of dollars in medical costs,” added Michlin.
Established in 1964, Yissum Research Development Company of the Hebrew University of Jerusalem protects and commercialises the Hebrew University’s intellectual property.
